Realworld efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Author：

E-ISSN： 1792-1082|11|2|1581-1585

ISSN： 1792-1074

Source： Oncology Letters, Vol.11, Iss.2, 2016-01, pp. : 1581-1585

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Severe colitis while responding to ipilimumab in metastatic melanoma

By Slingerland Marije Nortier Johan W. R. Veenendaal Roeland A. Kapiteijn Ellen

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 805-807

Informa Healthcare

Access to resources Recommend Favorite

Ipilimumab: showing survival benefit in metastatic melanoma

By Minchom Anna Young Kate Larkin James

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1255-1264

Future Medicine

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 105-113

Bentham Science Publishers

Access to resources Recommend Favorite

Melanoma Vaccines: The Potential for Clinical Efficacy with Minimal Toxicity in the Adjuvant Setting

By Michael S. Sabel Vernon K. Sondak

American Journal of Cancer, Vol. 3, Iss. 6, 2004-01 ,pp. : 377-386

Adis International

Access to resources Recommend Favorite

Oblimersen in the treatment of metastatic melanoma

By Tarhini Ahmad A Kirkwood John M

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 263-271

Future Medicine

Access to resources Recommend Favorite